POS0135 REDUCING IMMUNOGENICITY OF PEGLOTICASE (RECIPE) WITH CONCOMITANT USE OF MYCOPHENOLATE MOFETIL IN PATIENTS WITH REFRACTORY GOUT: A PHASE II RANDOMIZED CONTROLLED TRIAL

• Published in: Annals of the rheumatic diseases Vol. 80; no. Suppl 1; pp. 279 - 280
• Main Authors: Khanna, P., Khanna, D., Cutter, G., Foster, J., Melnick, J., Jaafar, S., Biggers, S., Rahman, F., Kuo, H.C., Feese, M., Saag, K.
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier B.V 01.06.2021; Elsevier Limited
• Subjects: Adverse events; Allopurinol; Cardiovascular disease; Clinical trials; Coronary artery; Diabetes mellitus; Gout; Heart diseases; Immunogenicity; Immunomodulation; Metabolic syndrome; Mycophenolate mofetil; Mycophenolic acid; Patients; Pharmaceuticals; Placebos; Renal insufficiency; Urate oxidase; Uric acid; Vascular diseases

Pegloticase is a recombinant, pegylated uricase, used for treatment of gout patients who fail oral urate lowering therapy (ULT). Its use has been limited due to immunogenicity leading to infusion reactions.1 We evaluated if co-administration of an immunomodulatory agent could prolong the efficacy of...